ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Jatenzo: Promising results with oral testosterone undecanoate
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 210716" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.urologytimes.com/view/dose-titration-is-not-required-in-most-patients-receiving-oral-softgel-testosterone[/URL]</p><p></p><p></p><p><em><strong>A recent assessment of the oral soft gel formulation of testosterone undecanoate (TU, Jatenzo) indicates that dose titration is not required in most patients receiving the treatment.1</strong></em></p><p><em></em></p><p><em>The finding was part of a study presented at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting by Robert E. Dudley, Ph.D., and co-authors.</em></p><p><em></em></p><p><em><strong>For the study, the investigators performed pharmacokinetic (PK) simulations using a robust population PK model that was developed for testosterone in 474 men with hypogonadism who were treated with oral TU in previous PK studies.</strong> <strong><u>Average testosterone concentrations (Cavg) were derived from multiple serial blood samples collected over 24 hours for oral TU doses of 237 mg, 316 mg, and 396 mg twice daily</u>.</strong> The investigators calculated the percent of subjects with T levels within the eugonadal range (serum Cavg between 304 ng/dL and 1030 ng/dL) at each of the TU dose levels. To assess the frequency of real-world dose titration, prescription data were accessed from the Symphony PatientSource Patient Transactional Dataset.</em></p><p><em></em></p><p><em><strong>The investigators found that the percentage of subjects with steady-state Cavg within the eugonadal range for 237 mg, 316 mg, and 396 mg twice daily were 61%, 74%, and 74%, respectively. <u>These percentages corresponded to mean serum testosterone levels of 398 ng/dL, 560 ng/dL, and 728 ng/dL, respectively</u>. </strong>In addition, wrote the authors, “Early assessment of real-world prescribing data for JATENZO indicated 35% of patients underwent dose titration by month 5.”</em></p><p><em></em></p><p><em><strong>According to the investigators, their findings were consistent with initial real-world experience with <u>oral TU indicating that dose titration is not required in most patients</u>.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>“However,” wrote the authors, “because the <u>desired outcome of TRT therapy focuses on both T Cavg and symptomatic response, this oral TU formulation enables necessary dose adjustment when needed</u>.”</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 210716, member: 13851"] [URL unfurl="true"]https://www.urologytimes.com/view/dose-titration-is-not-required-in-most-patients-receiving-oral-softgel-testosterone[/URL] [I][B]A recent assessment of the oral soft gel formulation of testosterone undecanoate (TU, Jatenzo) indicates that dose titration is not required in most patients receiving the treatment.1[/B] The finding was part of a study presented at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting by Robert E. Dudley, Ph.D., and co-authors. [B]For the study, the investigators performed pharmacokinetic (PK) simulations using a robust population PK model that was developed for testosterone in 474 men with hypogonadism who were treated with oral TU in previous PK studies.[/B] [B][U]Average testosterone concentrations (Cavg) were derived from multiple serial blood samples collected over 24 hours for oral TU doses of 237 mg, 316 mg, and 396 mg twice daily[/U].[/B] The investigators calculated the percent of subjects with T levels within the eugonadal range (serum Cavg between 304 ng/dL and 1030 ng/dL) at each of the TU dose levels. To assess the frequency of real-world dose titration, prescription data were accessed from the Symphony PatientSource Patient Transactional Dataset. [B]The investigators found that the percentage of subjects with steady-state Cavg within the eugonadal range for 237 mg, 316 mg, and 396 mg twice daily were 61%, 74%, and 74%, respectively. [U]These percentages corresponded to mean serum testosterone levels of 398 ng/dL, 560 ng/dL, and 728 ng/dL, respectively[/U]. [/B]In addition, wrote the authors, “Early assessment of real-world prescribing data for JATENZO indicated 35% of patients underwent dose titration by month 5.” [B]According to the investigators, their findings were consistent with initial real-world experience with [U]oral TU indicating that dose titration is not required in most patients[/U]. “However,” wrote the authors, “because the [U]desired outcome of TRT therapy focuses on both T Cavg and symptomatic response, this oral TU formulation enables necessary dose adjustment when needed[/U].”[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Jatenzo: Promising results with oral testosterone undecanoate
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top